{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:38:07Z","timestamp":1776818287298,"version":"3.51.2"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mycosis fungoides is recognized as an indolent cutaneous malignant T-cell lymphoma. In contrast, there are few therapeutic options for advanced forms of mycosis fungoides. Since immunotherapy is desirable as an alternative therapeutic option, identifying candidate molecules is an important goal for clinicians. Although tumor-derived negative immunomodulatory molecules, such as PD-1\/PD-L1, have been identified in various malignancies, the useful positive immunological drivers of mycosis fungoides are largely unknown. We found that the stimulator of interferon (IFN) genes (STING) was highly upregulated in early-stage mycosis fungoides. Immunohistochemical examination revealed different STING staining patterns in patients with mycosis fungoides. Although there were no significant differences in clinical factors\u2019 characteristics, STING expression was associated with the survival of patients with mycosis fungoides. The survival rate was significantly poor in patients with low STING-expressing mycosis fungoides. Univariate and multivariate analyses revealed that low STING expression was associated with an increased hazard ratio. Our results indicate that STING expression independently influences the prognosis of mycosis fungoides.<\/jats:p>","DOI":"10.1038\/s41598-022-17122-1","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T06:37:31Z","timestamp":1658990251000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["STING expression is an independent prognostic factor in patients with mycosis fungoides"],"prefix":"10.1038","volume":"12","author":[{"given":"Reiko","family":"Takayanagi-Hara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Sugino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Minokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Kawahara-Nanamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misa","family":"Itamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Kaneoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuko","family":"Saito-Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayo","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"issue":"1","key":"17122_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/1523-1747.ep12521312","volume":"75","author":"EH Epstein Jr","year":"1980","unstructured":"Epstein, E. H. Jr. Mycosis fungoides: Clinical course and cellular abnormalities. J. Invest. Dermatol. 75(1), 103\u2013106 (1980).","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"17122_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2340\/00015555-0831","volume":"90","author":"Y Sawada","year":"2010","unstructured":"Sawada, Y. et al. CD8+ CD56\u2009+ mycosis fungoides with an indolent clinical behaviour: Case report and literature review. Acta. Derm. Venereol. 90(5), 525\u2013526 (2010).","journal-title":"Acta. Derm. Venereol."},{"issue":"2","key":"17122_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jaad.2013.08.033","volume":"70","author":"SI Jawed","year":"2014","unstructured":"Jawed, S. I., Myskowski, P. L., Horwitz, S., Moskowitz, A. & Querfeld, C. Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): Part II. prognosis, management, and future directions. J. Am. Acad. Dermatol. 70(2), 223 (2014).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"11","key":"17122_CR4","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","volume":"17","author":"FS Hodi","year":"2016","unstructured":"Hodi, F. S. et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 17(11), 1558\u20131568 (2016).","journal-title":"Lancet Oncol."},{"issue":"2","key":"17122_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang, Y. K. et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23(2), 234\u2013247 (2022).","journal-title":"Lancet Oncol."},{"issue":"7","key":"17122_CR6","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","volume":"17","author":"JS Weber","year":"2016","unstructured":"Weber, J. S. et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): An open-label, randomised, phase 2 trial. Lancet Oncol. 17(7), 943\u2013955 (2016).","journal-title":"Lancet Oncol."},{"issue":"5","key":"17122_CR7","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/1097-0142(195309)6:5<1040::AID-CNCR2820060525>3.0.CO;2-5","volume":"6","author":"WC Sumner","year":"1953","unstructured":"Sumner, W. C. Spontaneous regression of melanoma. Cancer 6(5), 1040\u20131043 (1953).","journal-title":"Cancer"},{"issue":"4911","key":"17122_CR8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1136\/bmj.1.4911.458","volume":"1","author":"VB Levison","year":"1955","unstructured":"Levison, V. B. Spontaneous regression of a malignant melanoma. Br. Med. J. 1(4911), 458\u2013459 (1955).","journal-title":"Br. Med. J."},{"issue":"4","key":"17122_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/archderm.113.4.513","volume":"113","author":"VP Burby","year":"1977","unstructured":"Burby, V. P. The case of the vanishing lesions: Mycosis fungoides [proceedings]?. Arch Dermatol. 113(4), 513 (1977).","journal-title":"Arch Dermatol."},{"issue":"12","key":"17122_CR10","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1002\/ccr3.3171","volume":"8","author":"N Kubo","year":"2020","unstructured":"Kubo, N., Itoh, M., Watanabe, Y., Nobeyama, Y. & Asahina, A. Regression of CD30-positive large cell transformation arising on patch lesion of early mycosis fungoides. Clin. Case Rep. 8(12), 2418\u20132422 (2020).","journal-title":"Clin. Case Rep."},{"issue":"5","key":"17122_CR11","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jaad.2011.12.027","volume":"67","author":"HM Prince","year":"2012","unstructured":"Prince, H. M. et al. Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides\/S\u00e9zary syndrome receiving placebo. J. Am. Acad. Dermatol. 67(5), 867\u2013875 (2012).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5 Pt 2","key":"17122_CR12","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S0190-9622(97)80016-3","volume":"37","author":"T Sorrells","year":"1997","unstructured":"Sorrells, T., Pratt, L., Newton, J., Graham, S. & Ryan, M. Spontaneous regression of granulomatous mycosis fungoides in an HIV positive patient. J. Am. Acad. Dermatol. 37(5 Pt 2), 876\u2013880 (1997).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"9","key":"17122_CR13","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.1972.03210090052026","volume":"222","author":"EJ Van Scott","year":"1972","unstructured":"Van Scott, E. J. Complete regressions of mycosis fungoides with topical mechlorethamine hydrochloride. JAMA 222(9), 1172 (1972).","journal-title":"JAMA"},{"issue":"5","key":"17122_CR14","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/ced.13341","volume":"43","author":"RE Watchorn","year":"2018","unstructured":"Watchorn, R. E., Pawade, J. & Wachsmuth, R. C. Unilesional CD30+ mycosis fungoides with large cell transformation and spontaneous regression, masquerading as verruca vulgaris. Clin. Exp. Dermatol. 43(5), 633\u2013635 (2018).","journal-title":"Clin. Exp. Dermatol."},{"issue":"1","key":"17122_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.1990.8.1.155","volume":"8","author":"EC Kohn","year":"1990","unstructured":"Kohn, E. C. et al. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the S\u00e9zary syndrome. J. Clin. Oncol. 8(1), 155\u2013160 (1990).","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"17122_CR16","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin, A. M. et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study. J. Clin. Oncol. 34(23), 2698\u20132704 (2016).","journal-title":"J. Clin. Oncol."},{"key":"17122_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jdcr.2020.12.033","volume":"9","author":"JA Marks","year":"2021","unstructured":"Marks, J. A., Parker, D. C., Garrot, L. C. & Lechowicz, M. J. Nivolumab-associated cutaneous T-cell lymphoma. JAAD Case Reports. 9, 39\u201341 (2021).","journal-title":"JAAD Case Reports."},{"issue":"9","key":"17122_CR18","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1158\/2326-6066.CIR-13-0123","volume":"2","author":"D Chandra","year":"2014","unstructured":"Chandra, D. et al. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol. Res. 2(9), 901\u2013910 (2014).","journal-title":"Cancer Immunol. Res."},{"issue":"22","key":"17122_CR19","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.3390\/cancers13225603","volume":"13","author":"S Sato","year":"2021","unstructured":"Sato, S., Sawada, Y. & Nakamura, M. STING signaling and skin cancers. Cancers 13(22), 5603 (2021).","journal-title":"Cancers"},{"issue":"3","key":"17122_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41577-021-00572-5","volume":"22","author":"Q Xiao","year":"2022","unstructured":"Xiao, Q., McAtee, C. K. & Su, X. Phase separation in immune signalling. Nat. Rev. Immunol. 22(3), 188\u2013199 (2022).","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"17122_CR21","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1172\/JCI86892","volume":"126","author":"L Corrales","year":"2016","unstructured":"Corrales, L., McWhirter, S. M., Dubensky, T. W. Jr. & Gajewski, T. F. The host STING pathway at the interface of cancer and immunity. J. Clin. Investig. 126(7), 2404\u20132411 (2016).","journal-title":"J. Clin. Investig."},{"issue":"3","key":"17122_CR22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41577-021-00572-5","volume":"22","author":"Q Xiao","year":"2021","unstructured":"Xiao, Q., McAtee, C. K. & Su, X. Phase separation in immune signalling. Nat. Rev. Immunol. 22(3), 188\u2013199 (2021).","journal-title":"Nat. Rev. Immunol."},{"issue":"59","key":"17122_CR23","doi-asserted-by":"publisher","first-page":"eabe1935","DOI":"10.1126\/sciimmunol.abe1935","volume":"6","author":"Y Sawada","year":"2021","unstructured":"Sawada, Y. et al. Cutaneous innate immune tolerance is mediated by epigenetic control of MAP2K3 by HDAC8\/9. Sci. Immunol. 6(59), eabe1935 (2021).","journal-title":"Sci. Immunol."},{"issue":"1","key":"17122_CR24","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1038\/s41467-021-26240-9","volume":"12","author":"D Banerjee","year":"2021","unstructured":"Banerjee, D. et al. A non-canonical, interferon-independent signaling activity of cGAMP triggers DNA damage response signaling. Nat. Commun. 12(1), 6207 (2021).","journal-title":"Nat. Commun."},{"issue":"1","key":"17122_CR25","doi-asserted-by":"publisher","first-page":"7376","DOI":"10.1038\/s41598-020-64408-3","volume":"10","author":"LK Zebertavage","year":"2020","unstructured":"Zebertavage, L. K., Alice, A., Crittenden, M. R. & Gough, M. J. Transcriptional upregulation of NLRC5 by radiation drives STING- and interferon-independent MHC-I expression on cancer cells and T Cell cytotoxicity. Sci. Rep. 10(1), 7376 (2020).","journal-title":"Sci. Rep."},{"key":"17122_CR26","doi-asserted-by":"publisher","first-page":"39858","DOI":"10.1038\/srep39858","volume":"7","author":"S Song","year":"2017","unstructured":"Song, S. et al. Decreased expression of STING predicts poor prognosis in patients with gastric cancer. Sci. Rep. 7, 39858 (2017).","journal-title":"Sci. Rep."},{"key":"17122_CR27","doi-asserted-by":"crossref","unstructured":"Sun, Q., Fu, Y., Chen, X., Li, L., Wu, H., Liu, Y., et al. Prognostic perspectives of STING and PD-L1 expression and correlation with the prognosis of epstein-barr virus-associated gastric cancers. Gut Liver (2022).","DOI":"10.5009\/gnl210359"},{"issue":"6","key":"17122_CR28","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/jso.26804","volume":"125","author":"Z Lohinai","year":"2022","unstructured":"Lohinai, Z. et al. Loss of STING expression is prognostic in non-small cell lung cancer. J. Surg. Oncol. 125(6), 1042\u20131052 (2022).","journal-title":"J. Surg. Oncol."},{"issue":"3","key":"17122_CR29","first-page":"1256","volume":"11","author":"G Zhong","year":"2018","unstructured":"Zhong, G. et al. Expression of STING and PD-L1 in colorectal cancer and their correlation with clinical prognosis. Int. J. Clin. Exp. Pathol. 11(3), 1256\u20131264 (2018).","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"1","key":"17122_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/bjd.19669","volume":"185","author":"MH Vermeer","year":"2021","unstructured":"Vermeer, M. H., Nicolay, J. P., Scarisbrick, J. J. & Zinzani, P. L. The importance of assessing blood tumour burden in cutaneous T-cell lymphoma. Br. J. Dermatol. 185(1), 19\u201325 (2021).","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"17122_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/cyto.b.21870","volume":"100","author":"J Guitart","year":"2021","unstructured":"Guitart, J. S\u00e9zary syndrome and mycosis fungoides flow cytometric evaluation: The clinicians\u2019 perspective. Cytometry B Clin. Cytom. 100(2), 129\u2013131 (2021).","journal-title":"Cytometry B Clin. Cytom."},{"issue":"1","key":"17122_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/bjd.21053","volume":"187","author":"MH Vermeer","year":"2022","unstructured":"Vermeer, M. H., Moins-Teisserenc, H., Bagot, M., Quaglino, P. & Whittaker, S. Flow cytometry for the assessment of blood tumour burden in cutaneous T-cell lymphoma: Towards a standardized approach. Br. J. Dermatol. 187(1), 21\u201328 (2022).","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"17122_CR33","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"E Olsen","year":"2007","unstructured":"Olsen, E. et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the international society for cutaneous lymphomas (ISCL) and the cutaneous lymphoma task force of the european organization of research and treatment of cancer (EORTC). Blood 110(6), 1713\u20131722 (2007).","journal-title":"Blood"},{"issue":"14","key":"17122_CR34","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-12-0292","volume":"18","author":"Y Sawada","year":"2012","unstructured":"Sawada, Y. et al. Defective epidermal innate immunity and resultant superficial dermatophytosis in adult T-cell leukemia\/lymphoma. Clin. Cancer Res. 18(14), 3772\u20133779 (2012).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"17122_CR35","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1038\/s41598-021-85009-8","volume":"11","author":"M Yoshioka","year":"2021","unstructured":"Yoshioka, M. et al. High S100A2 expression in keratinocytes in patients with drug eruption. Sci. Rep. 11(1), 5493 (2021).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17122-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17122-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17122-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T04:46:25Z","timestamp":1669351585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17122-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["17122"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-17122-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"assertion":[{"value":"6 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12739"}}